title: High-dose cyclophosphamide for graft-versus-host disease prevention.
abstract: OBJECTIVE
  Administration of high-dose cyclophosphamide after transplantation inhibits both graft rejection and graft-versus-host disease (GvHD) in mouse models of allogeneic blood or marrow transplantation (alloBMT). This strategy has recently been adapted to human transplantation.
  
  
  RESULTS
  The safety and efficacy of high-dose posttransplantation cyclophosphamide, when given in combination with tacrolimus and mycophenolate mofetil, was first demonstrated after nonmyeloablative conditioning and allografting using human leukocyte antigen (HLA)-mismatched related donors. Further analysis shows that increasing HLA disparity does not worsen overall outcome. High-dose posttransplantation cyclophosphamide was also found to be effective as sole prophylaxis of acute and chronic GvHD after HLA-matched alloBMT.
  
  
  CONCLUSIONS
  Taking advantage of the differential susceptibility of proliferating, alloreactive T cells over nonproliferating, nonalloreactive T cells to high-dose cyclophosphamide, and owing to the drug's stem cell sparing effects, this novel strategy provides a unique opportunity to optimize GvHD prophylaxis after HLA-matched alloBMT and increase the use of HLA-mismatched related donors. Well tolerated and effective mismatched related alloBMT provides access to essentially everyone, such as patients with sickle cell anemia, in need of the procedure.
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA. luznile@jhmi.edu
authors.forename: Leo
authors.initials: L
authors.lastname: Luznik
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Jones
authors.forename: Ephraim J
authors.initials: EJ
authors.lastname: Fuchs
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006084:Graft Rejection / Q000276:immunology; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051379:Mice
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide
references.citation: Blood. 2010 Apr 22;115(16):3224-30
references.pmid: 20124511
references.citation: Cell Cycle. 2008 Feb 15;7(4):458-62
references.pmid: 18235249
references.citation: Bone Marrow Transplant. 2009 Jun;43(12):969-70
references.pmid: 19139737
references.citation: Biol Blood Marrow Transplant. 2007 Dec;13(12):1461-8
references.pmid: 18022576
references.citation: Biol Blood Marrow Transplant. 2002;8(3):131-8
references.pmid: 11939602
references.citation: Curr Opin Oncol. 2009 Mar;21(2):158-61
references.pmid: 19532018
references.citation: Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 2):31-6
references.pmid: 16399599
references.citation: Bone Marrow Transplant. 2004 Oct;34(7):621-5
references.pmid: 15300236
references.citation: Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S18-27
references.pmid: 19857584
references.citation: Blood. 2003 Aug 15;102(4):1541-7
references.pmid: 12714500
references.citation: Blood. 1995 May 15;85(10):2742-6
references.pmid: 7742535
references.citation: Immunol Rev. 1985 Dec;88:169-92
references.pmid: 3910556
references.citation: Blood. 2003 Jul 15;102(2):756-62
references.pmid: 12663454
references.citation: Hum Immunol. 1990 Oct;29(2):79-91
references.pmid: 2249952
references.citation: J Clin Oncol. 1997 May;15(5):1767-77
references.pmid: 9164184
references.citation: Blood. 2001 Nov 15;98(10):3174-5
references.pmid: 11721685
references.citation: J Clin Oncol. 2008 Dec 10;26(35):5728-34
references.pmid: 18981462
references.citation: Biol Blood Marrow Transplant. 2009 Jan;15(1):109-17
references.pmid: 19135949
references.citation: Lancet. 2005 Aug 27-Sep 2;366(9487):733-41
references.pmid: 16125590
references.citation: Lancet. 2009 May 2;373(9674):1550-61
references.pmid: 19282026
references.citation: Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505
references.pmid: 15983549
references.citation: Blood. 1991 Apr 1;77(7):1423-8
references.pmid: 2009366
references.citation: Biol Blood Marrow Transplant. 2010 Apr;16(4):482-9
references.pmid: 19925877
references.citation: Blood. 2004 Dec 1;104(12):3501-6
references.pmid: 15292060
references.citation: Bone Marrow Transplant. 2008 Oct;42(8):523-7
references.pmid: 18622413
references.citation: Blood. 2001 Jun 1;97(11):3390-400
references.pmid: 11369628
references.citation: Blood. 1998 Oct 1;92(7):2303-14
references.pmid: 9746768
references.citation: Blood. 2000 Sep 15;96(6):2062-8
references.pmid: 10979948
references.citation: Nat Med. 1999 Nov;5(11):1298-302
references.pmid: 10545997
references.citation: Blood. 2001 Dec 1;98(12):3456-64
references.pmid: 11719388
references.citation: Blood. 2007 Apr 1;109(7):3108-14
references.pmid: 17138818
references.citation: Transplantation. 1971 Apr;11(4):378-82
references.pmid: 4934348
references.citation: Lancet. 2005 May 7-13;365(9471):1647-56
references.pmid: 15885298
references.citation: Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50
references.pmid: 18489989
references.citation: Biol Blood Marrow Transplant. 2002;8(7):377-86
references.pmid: 12171484
references.citation: N Engl J Med. 2007 Oct 11;357(15):1472-5
references.pmid: 17928594
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5695-702
references.pmid: 17116940
references.citation: Curr Opin Immunol. 1993 Oct;5(5):800-3
references.pmid: 8240743
references.citation: J Immunol. 1992 Oct 15;149(8):2668-74
references.pmid: 1401906
references.citation: Transplantation. 1972 Mar;13(3):300-5
references.pmid: 5021439
references.citation: Science. 1988 Sep 23;241(4873):1655-8
references.pmid: 3262237
references.citation: Blood. 2005 Nov 1;106(9):3308-13
references.pmid: 16046530
references.citation: Clin Exp Immunol. 2002 May;128(2):255-66
references.pmid: 11985515